HCC and iCCA are molecularly very distinct entities: while in iCCA, driver mutations in oncogenes, including Kirsten rat sarcoma virus (KRAS), are frequently reported [4], in HCC RAS and rapidly accelerated fibrosarcoma (RAF) mutations occur only in a subfraction of less than 5 percent of cases [5]. This evidence concerns the gene KRAS and hepatocellular carcinoma.